U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07176923) titled 'CS-121 APOC3 Base Editing in FCS' on Aug. 30.
Brief Summary: This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia syndrome (FCS).
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Familial Chylomicronemia Syndrome (FCS)
Intervention:
BIOLOGICAL: CS-121
CS-121 is a in vivo base editing therapy formulated in lipid nanoparticles for targeted editin...